Ri­bon Ther­a­peu­tics rids pre­clin­i­cal work, trims staff to fo­cus on two clin­i­cal PARP in­hibitors

Ri­bon Ther­a­peu­tics, a biotech look­ing to make next-gen­er­a­tion oral PARP in­hibitors, has end­ed pre­clin­i­cal and plat­form work to fo­cus on two clin­i­cal pro­grams.

“Cuts across the or­ga­ni­za­tion” were made to the ap­prox­i­mate­ly 60-em­ploy­ee biotech, chief busi­ness of­fi­cer Gary Sut­ton con­firmed to End­points News in an email. He de­clined to dis­close the num­ber of em­ploy­ees im­pact­ed by the lay­offs.

“We great­ly ap­pre­ci­ate the con­tri­bu­tions from our team and came to our de­ci­sion af­ter care­ful­ly con­sid­er­ing what was best for our clin­i­cal pro­grams and the pa­tients they could po­ten­tial­ly serve,” Sut­ton said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER